Savior LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Savior LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3	Closed	-$1K	–	890
2019 Q4	$1K	Buy	+3	New	+$1.01K	﹤0.01%	860

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Savior LLC's REGN Position: Q1 2020 in Review

Savior LLC sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 3 shares — an estimated $1K sold.

Savior LLC first reported a position in REGN in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

Savior LLC reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Savior LLC sold 3 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $1K.
Savior LLC first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Savior LLC's Regeneron Pharmaceuticals position peaked at $1K in Q4 2019.
816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on Savior LLC's 13F filing for Q1 2020, filed 22 Apr 2020.